Spectrum Pharmaceuticals has been granted a patent for the crystalline forms of a quinazoline compound and its hydrochloride salts. The patent covers the preparation method for the compound 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one and its hydrochloride salts. GlobalData’s report on Spectrum Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Spectrum Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Spectrum Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Spectrum Pharmaceuticals's grant share as of February 2024 was 56%. Grant share is based on the ratio of number of grants to total number of patents.

Crystalline form of quinazoline compound and hydrochloride salts

Source: United States Patent and Trademark Office (USPTO). Credit: Spectrum Pharmaceuticals Inc

The granted patent (Publication Number: US11883402B2) discloses a crystalline form of a compound with Chemical formula (1), along with various specific characteristics and methods of preparation. The crystalline form of the compound is described in different variations (a, b, c, d, e) with specific 13C solid-state nuclear magnetic resonance (ssNMR) spectra for each variation. The patent also covers a pharmaceutical composition containing the crystalline form of the compound along with pharmaceutically acceptable carriers or diluents, with a chemical purity of over 95%.

Furthermore, the patent includes a method for treating cancer by administering the pharmaceutical composition to subjects with various types of cancer, including non-small cell lung cancer, oral cancer, gastrointestinal cancer, and others. Additionally, the patent details a method for preparing the crystalline form of the compound through specific steps involving the preparation of dihydrate, anhydrous forms I and II, monohydrochloride monohydrate, and anhydrous monohydrochloride crystalline form. The patent also mentions the use of non-protic polar solvents like DMSO or DMF in the preparation process. Moreover, a kit comprising the crystalline form of the compound along with cytotoxic agents and molecularly targeted agents is also disclosed, with specific examples of agents like taxanes, VEGF inhibitors, and EGFR family inhibitors.

To know more about GlobalData’s detailed insights on Spectrum Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies